Dr Stephen Mullin
Clinical Lectureship In Neurology
Clinical Trials & Health Research - Institute of Translational & Stratified Medicine (Faculty of Medicine and Dentistry)
I am a neurologist and clinical academic with a research interest in Parkinson disease. My primary interest is the genetic and clinical stratification of the risk of Parkinson disease for targeting of novel neuroprotective compounds. I also have expertise in clinical trial design and implementation and internet based clinical assessment in Parkinson disease. To date the majority of my research has centered on the glucocerebrosidase (GBA) pathway, numerically the most significant genetic risk factor for Parkinson disease. This included the day to day running of a phase II clinical trial of ambroxol, a putative neuroprotective and small molecular chaperone of the glucocerebrosidase enzyme (GCase). Additionally I jointly run an internet based cohort study, Rapsodi, which aims to stratify GBA mutations carriers without Parkinson disease in terms of their disease risk using clinical, genetic and biochemical parameters. The ultimate of this study is to provide a cost effective platform for targeting of future neuroprotective compounds.
BSc. Medical Sciences, University College London, 2006.
MBBS. Medicine, Imperial College London, 2008.
MRCP, Royal College of Physicians, 2012 .
Molecular Neurology and Therapeutics course, Wellcome Trust, 2014.
Advanced course is epidemiology and statistics, London School of Hygiene and Tropical Medicine, 2017.
PhD. Neuroscience, University College London, 2018
Specialty Certificate Examination in Neurology, Royal College of Physicians, 2019
Key publications are highlightedJournals
Reports & invited lectures
- The GBA gene and the early signs of Parkinson's
- Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment. Italian Society of Neuroscience. Ischia, Oct. 2017